VCCRI: 'Heart in a Box'

An Australian method of preserving donated hearts has boosted the number of successful transplants across the world, with new research demonstrating similar survival rates to traditional transplants.

VCCRI: 'Heart in a Box'

September 6, 2022
An Australian method of preserving donated hearts has boosted the number of successful transplants across the world, with new research demonstrating similar survival rates to traditional transplants.
Read Transcript

An Australian method of preserving donated hearts has boosted the number of successful transplants and new data shows recipients of these “dead” tickers have similar survival rates to traditional transplants.

There have been 78 heart transplants conducted through Sydney’s St Vincent’s Hospital and the Victor Chang Cardiac Research Institute’s world-first DCD (donation after circulatory death) process, a technique that has since been adopted by several hospitals abroad.

While donated hearts once had to come from brain-dead people whose hearts were still beating, the DCD method, pioneered in Sydney, means donations can take place after the heart has stopped. Within half an hour of life support being switched off, the heart is extracted and flushed with an oxygenated blood preservation solution before being transported in a special machine to its recipient.

“These are hearts that would not otherwise have been used,” said Professor Peter MacDonald, a senior cardiologist at St Vincent’s Hospital and leader of the DCD heart transplant team.

When Sydneysider Ross Tripodi woke up from his DCD heart transplant in April 2020, he assumed it must not have happened: he didn’t feel like he had just had a big surgery, he felt better than before.

“I was bright-eyed and bushy-tailed,” the 57-year-old recalled. “I turned to the nurse and said, ‘Oh, you haven’t done the transplant?’”

Tripodi was diagnosed with cardiomyopathy – an enlarged heart – aged 49. In 2019, experiencing organ failure, he was warned he would not survive another year without a transplant.

“I got home to see my daughter turn 21, most people take that for granted, but, for me, it was a lot,” he said. “There’s never a bad day anymore. You don’t sweat the little things. I’m just grateful for anything.”

A review of the first eight years of the program, published in the journal Transplantation, showed the new technology had increased the number of transplants performed at the hospital by 25 per cent.

It also demonstrated, in its small sample of 74 transplants, a negligible difference in one-year and five-year survival rates between people who received a heart via either method.

The review’s lead author Dr Yashutosh Joshi said it demonstrated there was “no reason why we shouldn’t” pursue DCD when appropriate for the patient. The five-year survival rate for a DCD heart transplant was 88 per cent, compared with 81 per cent for a brain-dead transplant.

“We don’t want to overstate the benefits of DCD over brain death because it’s still a small sample,” MacDonald said, noting heart transplant was generally a very successful procedure.

The newer method also comes with a time pressure that does not exist in traditional heart transplants. Joshi – who has travelled to collect donated hearts from as far as Darwin – described the program as “essentially 24/7”, with minutes saved by harvesting the organ in an anaesthetic bay, as opposed to in intensive care, contributing to success.

But, said Dr Emily Granger, a surgeon at St Vincent’s, the hearts donated through the DCD system are generally of better quality.

“When someone is brain-dead they have often had a surge of adrenaline which impacts the heart, but in these people their heart is in much better condition,” said Granger, who is also the president-elect of the Australian and New Zealand Society of Cardiac and Thoracic Surgeons.

At St Vincent’s, the only Australian hospital using the method, DCD procedures now account for 30 per cent of heart transplants. In the UK, where DCD transplants started in 2015, they account for almost half of procedures.

Hospitals in the US, Spain, Belgium and the Netherlands have also adopted the technology.

MacDonald said he expected the cost of the “heart in a box” – about $50,000 per use – would mean that it would probably never make up the majority of transplants, but it was an important way to increase organ donation.

The Organ and Tissue Authority’s national medical director, Associate Professor Helen Opdam, agreed, noting the pandemic had impacted the number of available donors and people receiving transplants.

“Heart transplantation from donation after circulatory death enables more people to have their wishes to donate honoured, as it has expanded the situations in which donation is possible,” she said. “It also means more people will have the chance to receive a life-saving heart transplant.”

St Vincent’s and the Victor Chang Cardiac Research Institute are now working with researchers at the University of Queensland to improve the viability of donated hearts, through a novel project involving the use of protein from funnel web spider venom in the preservation process.

 This article was originally posted by The Sydney Morning Herald here.

Licensed by Copyright Agency. You must not copy this work without permission.

An Australian method of preserving donated hearts has boosted the number of successful transplants and new data shows recipients of these “dead” tickers have similar survival rates to traditional transplants.

There have been 78 heart transplants conducted through Sydney’s St Vincent’s Hospital and the Victor Chang Cardiac Research Institute’s world-first DCD (donation after circulatory death) process, a technique that has since been adopted by several hospitals abroad.

While donated hearts once had to come from brain-dead people whose hearts were still beating, the DCD method, pioneered in Sydney, means donations can take place after the heart has stopped. Within half an hour of life support being switched off, the heart is extracted and flushed with an oxygenated blood preservation solution before being transported in a special machine to its recipient.

“These are hearts that would not otherwise have been used,” said Professor Peter MacDonald, a senior cardiologist at St Vincent’s Hospital and leader of the DCD heart transplant team.

When Sydneysider Ross Tripodi woke up from his DCD heart transplant in April 2020, he assumed it must not have happened: he didn’t feel like he had just had a big surgery, he felt better than before.

“I was bright-eyed and bushy-tailed,” the 57-year-old recalled. “I turned to the nurse and said, ‘Oh, you haven’t done the transplant?’”

Tripodi was diagnosed with cardiomyopathy – an enlarged heart – aged 49. In 2019, experiencing organ failure, he was warned he would not survive another year without a transplant.

“I got home to see my daughter turn 21, most people take that for granted, but, for me, it was a lot,” he said. “There’s never a bad day anymore. You don’t sweat the little things. I’m just grateful for anything.”

A review of the first eight years of the program, published in the journal Transplantation, showed the new technology had increased the number of transplants performed at the hospital by 25 per cent.

It also demonstrated, in its small sample of 74 transplants, a negligible difference in one-year and five-year survival rates between people who received a heart via either method.

The review’s lead author Dr Yashutosh Joshi said it demonstrated there was “no reason why we shouldn’t” pursue DCD when appropriate for the patient. The five-year survival rate for a DCD heart transplant was 88 per cent, compared with 81 per cent for a brain-dead transplant.

“We don’t want to overstate the benefits of DCD over brain death because it’s still a small sample,” MacDonald said, noting heart transplant was generally a very successful procedure.

The newer method also comes with a time pressure that does not exist in traditional heart transplants. Joshi – who has travelled to collect donated hearts from as far as Darwin – described the program as “essentially 24/7”, with minutes saved by harvesting the organ in an anaesthetic bay, as opposed to in intensive care, contributing to success.

But, said Dr Emily Granger, a surgeon at St Vincent’s, the hearts donated through the DCD system are generally of better quality.

“When someone is brain-dead they have often had a surge of adrenaline which impacts the heart, but in these people their heart is in much better condition,” said Granger, who is also the president-elect of the Australian and New Zealand Society of Cardiac and Thoracic Surgeons.

At St Vincent’s, the only Australian hospital using the method, DCD procedures now account for 30 per cent of heart transplants. In the UK, where DCD transplants started in 2015, they account for almost half of procedures.

Hospitals in the US, Spain, Belgium and the Netherlands have also adopted the technology.

MacDonald said he expected the cost of the “heart in a box” – about $50,000 per use – would mean that it would probably never make up the majority of transplants, but it was an important way to increase organ donation.

The Organ and Tissue Authority’s national medical director, Associate Professor Helen Opdam, agreed, noting the pandemic had impacted the number of available donors and people receiving transplants.

“Heart transplantation from donation after circulatory death enables more people to have their wishes to donate honoured, as it has expanded the situations in which donation is possible,” she said. “It also means more people will have the chance to receive a life-saving heart transplant.”

St Vincent’s and the Victor Chang Cardiac Research Institute are now working with researchers at the University of Queensland to improve the viability of donated hearts, through a novel project involving the use of protein from funnel web spider venom in the preservation process.

 This article was originally posted by The Sydney Morning Herald here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by Sydney Morning Herald, published on September 6, 2022. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
November 22, 2023

Impact Video Series: RPA Green Light Institute

We interviewed leading individuals from The Royal Prince Alfred Hospital Green Light Institute to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.

Read More
HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).
May 4, 2026

How science turned back the clock of human development to create a miracle blood stem cell

Many thought it could never be done. But three Murdoch Children’s Research Institute scientists recreated embryonic development to crack the blood stem cell code.

Read More
December 5, 2023

Prof Daniel MacArthur | 2023 Sohn Hearts & Minds Conference

At the 2023 Sohn Hearts & Minds Conference, we heard from Prof Daniel MacArthur, the Director of the Centre for Population Genomics.

Read More
December 5, 2023

Prof Michelle Simmons AO | Sohn Hearts & Minds Conference

At this year's Sohn Hearts & Minds Conference, we heard from Prof Michelle Simmons, the CEO and Founder of Silicon Quantum Computing.

Read More
Daniel MacArthur with Melbourne scientist and assistant professor Misty Jenkins. Both will be speaking at the Sohn Hearts & Minds conference in Sydney.Daniel MacArthur with Melbourne scientist and assistant professor Misty Jenkins. Both will be speaking at the Sohn Hearts & Minds conference in Sydney.Daniel MacArthur with Melbourne scientist and assistant professor Misty Jenkins. Both will be speaking at the Sohn Hearts & Minds conference in Sydney.Daniel MacArthur with Melbourne scientist and assistant professor Misty Jenkins. Both will be speaking at the Sohn Hearts & Minds conference in Sydney.
November 15, 2023

Advancing Medicine Is In Daniel MacArthur’s DNA

When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.

Read More
November 10, 2023

Big thinkers in hunt for brain cancer cure

“Brain cancer is rare, but for people who do get it the prognosis is not good,” Assistant Professor Jenkins tells The Australian.

Read More
April 20, 2023

Artificial intelligence gives new hope for sufferers of severe heart problem

New AI software can improve the diagnosis of severe aortic stenosis by 72% and could potentially change the lives of about 50,000 Australians with the life-threatening condition.

Read More
February 14, 2023

Bringing Equity and Diversity to Genomic Medicine

Professor Daniel MacArthur, Director of the Centre for Population Genomics has big goals to bring equity and diversity into genomic medicine in Australia, something surprisingly inadequate presently.

Read More
February 24, 2022

New Partnership with Cerebral Palsy Alliance

We’re excited to announce a new partnership with the Cerebral Palsy Alliance and are proud to be supporting this important research.

Read More
August 3, 2021

Australian breakthrough to stop heart arteries from clogging

Victor Chang scientist has led landmark research that has the potential to stop arteries of the heart from becoming clogged by targeting a particular gene.

Read More
June 9, 2020

Beneficiary Profile: Orygen

1 in 5 young people will have experienced a depressive episode by the time they are 18. With thanks to Cooper Investors and Hearts & Minds, we have been able to put youth mental health on the global agenda and progress our work in developing a global mental health framework.

Read More
November 22, 2019

Impact Video Series: Sydney Children's Hospital Foundation

We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.

Read More
November 22, 2019

Impact Video Series: The Florey Institute

We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.

Read More
November 22, 2019

Impact Video Series: Victor Chang

We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.

Read More
May 29, 2019

Winning Hearts and Minds

Mark Nelson of Caledonia discusses his connection with the Florey Institute, one of our beneficiaries, and why he's involved with Hearts and Minds.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.